Study of ZSP1273 in Patients With Acute Uncomplicated Influenza A

Summary

The purpose of this study is to evaluate the antiviral effect, as measured by the time to alleviation of influenza symptoms and viral titer in nasopharyngeal secretions in adults with acute uncomplicated influenza A following administration of ZSP1273.

Timeline

Start

2019-12-07

Primary completion

2020-05-18

Completion

2020-05-18

Outcome

Met primary endpoint

paper All three onradivir groups showed decreased median time to alleviate influenza symptoms PMID 38330975 ↗

paper The median difference between the onradivir 600 mg once per day group and the placebo group was -22·82 h (p=0·0330). PMID 38330975 ↗

Publications

• Yang Z, Li Z, Zhan Y, Lin Z, Fang Z, Xu X, Lin L, Li H, Lin Z, Kang C, Liang J, Liang S, Li Y, Li S, Yang X, Ye F, Zhong N; Onradivir Trial Recruitment and Medical Monitoring Group. Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2024 May;24(5):535-545. doi: 10.1016/S1473-3099(23)00743-0. Epub 2024 Feb 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Onradivir	Small molecule	200 mg	Oral
Subject	Onradivir	Small molecule	400 mg	Oral
Subject	Onradivir	Small molecule	600 mg	Oral

Indications